AGA Nanotech (UK) Wins the 2025 EWMA Innovation Competition

March 28, 2025 03:18 AM AEDT | By EIN Presswire
 AGA Nanotech (UK) Wins the 2025 EWMA Innovation Competition
Image source: EIN Presswire

The winner AGA Nanotech was recognized for its groundbreaking Battlestar™ antimicrobial delivery system and awarded 10.000 EUR. BARCELONA, CATALONIA, SPAIN, March 27, 2025 /EINPresswire.com/ -- The European Wound Management Association (EWMA) and the EWMA Innovation Alliance (EIA) proudly announce AGA Nanotech as the winner of the 2025 edition of the EWMA Innovation Competition – sponsored by Convatec, a global leader in medical products and technology and ProDevLabs, a leading pre-clinical and wound care CRO. The winner was recognized for its groundbreaking Battlestar™ antimicrobial delivery system, which demonstrates broad-spectrum efficacy against bacteria, fungi, viruses, and spores, with no risk of resistance.

During the EWMA Innovation Forum, CEO Harsha Siani accepted the €10,000 prize on behalf of AGA Nanotech.

Kirsi Isoherranen, President of EWMA, commented: "This prize honors solutions with the potential to enhance the quality and effectiveness of wound care, ultimately improving patients' lives. AGA Nanotech is a well-deserved winner of the 2025 EWMA Innovation Competition."

Sean Willis, Vice President, Research & Development, Advanced Wound Care at Convatec, said: "Many congratulations to the winner, Aga Nanotech, and their novel technology. It’s a highly innovative advancement adding to the crucial development and adoption of new and improved solutions in managing wounds."

Mitch Sanders, CEO at ProDevLabs said “It is crucial to facilitate the development and uptake of new and better solutions into clinical use as wounds are a burden on societies on a level with cancer. AGA Nanotech has developed a solution with the potential for investors and subsequent commercialization.

About Aga Nanotech:
AGA Nanotech is dedicated to preserving antibiotics, protecting patients, and preventing resistance through its innovative antimicrobial delivery system, Battlestar™. Battlestar™ offers an advanced, non-antibiotic solution that combats biofilms and multidrug-resistant infections while promoting healing. By generating reactive oxygen species (ROS) in situ, Battlestar™ targets multiple microbial pathways, providing broad-spectrum antimicrobial and antibiofilm activity.

For more information about Aga Nanotech, visit www.agananotech.com.

About EWMA (EMWA):
EWMA is a non-profit organization committed to advancing education and research in wound management. For more information about EWMA, visit www.ewma.org.

About EWMA Innovation Alliance (EIA):
EIA is a membership-based ecosystem dedicated to advancing innovation in wound care across Europe. For more information, visit www.ewmainnovationalliance.org.

About the EWMA Innovation Forum:
The EWMA Innovation Forum is an annual event organized by EIA addressing the unmet clinical needs in wound management.

About Convatec:
Convatec sponsored the EWMA Innovation Forum and Innovation Competition.

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin to improved patient outcomes and reduced care costs. Convatec’s revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com

Convatec contact:
[email protected]

About ProDevLabs:
ProDevLabs sponsored the EWMA Innovation Forum and Innovation Competition. ProDevLabs is a Premier Wound Care R&D and Preclinical CRO. We are a Full-Service CRO and can help clients navigate the process of commercializing a new product, with 30+ years’ experience in wound repair and regeneration, biologics, biomaterials, medical devices, and pharmaceuticals. Our expert Scientists and Business Advisors help clients steer through the uncertain waters to ensure speed to market and commercial success.

ProDevLabs contact:
CEO Mitch Sanders
[email protected]

Enquiries about EWMA Innovation Alliance and Competition
EWMA Innovation Alliance
Peter Frank, Coordinator
Email: [email protected]
Phone: +45 3842 958

Peter Frank
EWMA Innovation Alliance
+45 70 20 03 05
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.